Скачать или смотреть EPISODE #57 The Legal Global Cannabis Trade with Michael Patterson CEO at US Cannabis Pharmaceutica

This week we’re joined by the incredibly passionate Michael Patterson, cannabis expert and CEO at US Cannabis Pharmaceutical Research and Development. 

Together, we discuss Michael’s worldwide business operations, why big cannabis want a piece of the market in Europe, and the ways in which Covid-19 has affected the cannabis market.

Episode Summary• By training, Michael is a healthcare executive and occupational therapist and has a wealth of experience in the industry, including running a nursing home group worth $230m. 
• In 2014, Michael connected with a war veteran, Saul who had been using opiates for chronic back pain sustained in service. At the time, he was withdrawing from opiates and was interested in using medical cannabis for his pain. 
• This encounter inspired Michael to take action, and so he entered the cannabis industry to help other people like Saul.
• In 2014, Michael founded US Cannabis Pharmaceutical Research and Development. The company is focused on moving society forward through legalized Cannabis and Hemp. They consult, collaborate, and partner in all aspects of the industry including, but not limited to, investment analysis, R&D, operations and compliance management, international transport and trade, laws-regulation, technology (blockchain, crypto), licensing, banking, cultivation/processing/dispensing, and economic development. 
• The company currently have 5 medical cannabis licenses in Africa (Tanzania, Democratic Republic of Congo, Uganda, Zimbabwe, and Lesotho) and one in Portugal. They also import and export cannabis products into and out of Europe, and are contracted to grow cannabis for THC in Africa.
• Michael founded US Cannabis Pharmaceutical Research and Development are also working with companies across the world within the areas of software, blockchain, and cryptocurrency.
• THC is considered an ‘API’ or an Active Pharmaceutical Ingredient, which is then sold to pharmaceutical companies to process and make medicine from. 
• In the USA, the average proportion of a state who qualify for medical cannabis is 2-5%.
• Big Cannabis is interested in the European market as medicine in this part of the world tends to me more socialised and the government tends to pay for medicines. The population of Europe is much larger than the USA, so many of the big players from North America are hoping to gain market share in the EU as the market develops.
• CBD processing plants in the US are diversifying as there is a trend towards growing hemp for fibre and industrial uses.
• In the USA, access to cannabis is considered essential during Covid-19, which legitimises it as a medicine.
• 93% of Americans want medical cannabis legalised, and 65% want recreational cannabis legal. 
• Many of the states in the USA who did not previously allow home delivery have now been forced to due to the pandemic. Sales of flower and edibles have also risen during this time.
• Michael believes that public safety, patient access and commerce all need to work together in harmony for the system to become/remain successful.
•  

Quotables

Moving into 2021, you’re going to start to see a bigger interest from pharmaceutical companies who want to get more involved [with cannabis] 13:38

The EU is where to be. Everybody wants to be there. 14:20

Covid-19 will legitimise cannabis as a medicine 31:10

ResourcesJoin Michael on LinkedIn:   / michael-patterson-nha-otr-l-ceas-88485051  

USCPRD Website: http://www.uscprd.com/